Want to see FR:NANO full AI Analyst Report?
NANO Stock Chart & Stats
€35.24
-€0.84(-2.38%)
At close: 4:00 PM EDT
€35.24
-€0.84(-2.38%)
Day’s Range― - ―
52-Week Range€5.66 - €47.66
Previous CloseN/A
Volume28.17K
Average Volume (3M)654.19K
Market Cap
€1.71B
Enterprise Value€986.13
Total Cash (Recent Filing)€52.75M
Total Debt (Recent Filing)€95.32M
Price to Earnings (P/E)―
Beta0.75
Next Earnings
Sep 30, 2026EPS Estimate
-0.25Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.51
Shares Outstanding50,619,583
10 Day Avg. Volume711,483
30 Day Avg. Volume654,186
Financial Highlights & Ratios
PEG Ratio0.59
Price to Book (P/B)-10.94
Price to Sales (P/S)31.19
P/FCF Ratio-27.22
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€55.00Price Target Upside56.07% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)-0.21
Revenue Forecast (FY)€34.90M
Bulls Say, Bears Say
Bulls Say
Strategic Pharma PartnershipA multi-year collaboration with Janssen provides development resources, milestone/royalty potential and reduced commercialization burden. Structurally, such partnerships de-risk clinical programs, can provide non-dilutive funding and improve chances of eventual market access and scale.
Proprietary Nanoparticle PlatformThe NBTXR3 platform offers a differentiated mechanism to amplify radiotherapy and potentially boost immune response. Platform-driven products can address multiple tumor types and combination regimens, creating durable competitive advantages and a broader long-term addressable market if clinical efficacy is confirmed.
Favorable Unit Economics SignalA reported 100% gross margin in 2025 suggests attractive unit economics for the company’s offerings or milestone-driven revenue mix. If sustained through commercial adoption or recurring collaboration milestones, high gross margins enable operational leverage and support a clearer path to improving profitability over time.
Bears Say
Persistent Cash BurnConsistent negative operating and free cash flow indicate the company cannot self-fund development, increasing reliance on external capital. Over a multi-month horizon this elevates dilution and financing risk, constrains R&D pacing, and limits strategic optionality if markets or partners slow funding.
Negative Shareholders' Equity & Rising DebtA negative equity base combined with rising debt weakens the capital structure and increases financial fragility. This structural imbalance raises refinancing and covenant risk, may increase cost of capital, and reduces flexibility to invest or sustain prolonged clinical programs without dilutive financing.
Volatile Revenue And Ongoing LossesHighly variable top-line results and continued net losses make forecasting and scaling commercial operations difficult. Lumpy collaboration or milestone revenue can mask true demand, complicate resource planning and delay a consistent route to sustainable profits, prolonging dependence on external funding.
NANO FAQ
What was Nanobiotix SA’s price range in the past 12 months?
Nanobiotix SA lowest stock price was €5.66 and its highest was €47.66 in the past 12 months.
What is Nanobiotix SA’s market cap?
Nanobiotix SA’s market cap is €1.71B.
When is Nanobiotix SA’s upcoming earnings report date?
Nanobiotix SA’s upcoming earnings report date is Sep 30, 2026 which is in 60 days.
How were Nanobiotix SA’s earnings last quarter?
Currently, no data Available
Is Nanobiotix SA overvalued?
According to Wall Street analysts Nanobiotix SA’s price is currently Undervalued.
Does Nanobiotix SA pay dividends?
Nanobiotix SA does not currently pay dividends.
What is Nanobiotix SA’s EPS estimate?
Nanobiotix SA’s EPS estimate is -0.25.
How many shares outstanding does Nanobiotix SA have?
Nanobiotix SA has 50,619,583 shares outstanding.
What happened to Nanobiotix SA’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Nanobiotix SA?
Currently, no hedge funds are holding shares in FR:NANO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Nanobiotix SA
Nanobiotix S.A. operates as a clinical-stage biotechnology that focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer. The company has a partnership with Lian Oncology Limited to develop and commercialize NBTXR3 in Greater China, South Korea, Singapore, and Thailand. Nanobiotix S.A. was incorporated in 2003 and is based in Paris, France.
NANO Stock 12 Month Forecast
Average Price Target
€55.00
▲(56.07% Upside)
Technical Analysis
Innate Pharma SA
―
Transgene
―
OSE Immunotherapeutics SA
―
Cellectis SA
―
MaaT Pharma
―